Latest News

A daily dose of cotrimoxazole reduces illness among HIV-positive children in Africa, even after several years of HIV treatment. Not only does cotrimoxazole reduce the chances of children needing hospital treatment, it also saves the health system money. These findings from the ARROW trial in Uganda and Zimbabwe were published this month in the New England Journal of Medicine. Previous trials in Africa showed that cotrimoxazole prophylaxis reduces death and illness in children who are not yet on ART (pdf, 147kb), as it helps prevent infections while their immune systems are weak. Once children have been on ART for several […]

read more news stories

About Lablite

Lablite is an implementation project investigating strategies to roll out HIV treatment safely and cost-effectively in real-life settings in sub-Saharan Africa. The project is working closely with ministries of Health in 3 countries in Africa (Malawi, Zimbabwe and Uganda), and has the overall aim of evaluating rolling-out of antiretroviral therapy (ART) to smaller health centres, nearer to where people live, using a clinically-driven monitoring approach. It aims to inform national and international policy on how best to use the limited funds available to increase coverage of HIV treatment.

Lablite involves:

  • A situation analysis to map what is happening on the ground
  • A demonstration project to show how decentralised delivery of HIV treatment would work in lower level health centres with little or no laboratory facilities
  • Health economics and modelling work to assess the economic consequences of different HIV programmes

Read more about Lablite

Contact us

MRC Clinical Trials Unit at UCL,
Aviation House, 125 Kingsway
London
Postcode: WC2B 6NH
E-Mail: mrcctu.lablite@ucl.ac.uk